Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms

European Journal of Cancer

Volumn 51, Issue 18, 2015, Pages 2792-2799

  Johnson, Douglas B ^a   Menzies, Alexander M ^b,f,i   Zimmer, Lisa ^c   Eroglu, Zeynep ^d,e   Ye, Fei ^a   Zhao, Shilin ^a   Rizos, Helen ^f,g   Sucker, Antje ^c   Scolyer, Richard A ^b,h,i   Gutzmer, Ralf ^j   Gogas, Helen ^k   Kefford, Richard F ^b,f,g,i   Thompson, John F ^b,h,i   Becker, Jürgen C ^l   Berking, Carola ^m   Egberts, Friederike ⁿ   Loquai, Carmen ^o   Goldinger, Simone M ^p   Pupo, Gulietta M ^f   Hugo, Willy ^d   Kong, Xiangju ^d   Garraway, Levi A ^q   Sosman, Jeffrey A ^a   Ribas, Antoni ^d   Lo, Roger S ^d   Long, Georgina V ^b,f,i   Schadendorf, Dirk ^c   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^f WESTMEAD HOSPITAL   (Australia)

^g MACQUARIE UNIVERSITY   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^l UNIVERSITY HOSPITAL ESSEN   (Germany)

^m UNIVERSITY OF MUNICH   (Germany)

ⁿ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^o UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^p UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^q HARVARD MEDICAL SCHOOL   (United States)

more..

Author keywords

Acquired; BRAF; Dabrafenib; MAPK; MEK1; Meta analysis; NRAS; Resistance; Splice; Vemurafenib

Indexed keywords

DABRAFENIB; K RAS PROTEIN; LACTATE DEHYDROGENASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; ONCOGENE N RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; AUSTRALIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; EUROPE; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SKIN NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; AUSTRALIA; BIOMARKERS, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EUROPE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTATION; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RISK FACTORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84959536816     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.08.022     Document Type: Article

References (35)

1. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, and et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
2. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, and et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
3. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, and et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
4. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, M. Millward, and et al. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
5. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, and et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
6. H. Shi, G. Moriceau, X. Kong, M.K. Lee, H. Lee, R.C. Koya, and et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 2012 724
7. P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, G. Moriceau, and et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
8. N. Wagle, C. Emery, M.F. Berger, M.J. Davis, A. Sawyer, P. Pochanard, and et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J Clin Oncol 29 2011 3085 3096
9. H. Shi, A. Hong, X. Kong, R.C. Koya, C. Song, G. Moriceau, and et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition Cancer Discov 4 2014 69 79
10. K.H. Paraiso, Y. Xiang, V.W. Rebecca, E.V. Abel, Y.A. Chen, A.C. Munko, and et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Res 71 2011 2750 2760
11. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, L.A. Johnson, and et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
12. R. Haq, S. Yokoyama, E.B. Hawryluk, G.B. Jonsson, D.T. Frederick, K. McHenry, and et al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition Proc Natl Acad Sci USA 110 2013 4321 4326
13. A.A. Marusiak, Z.C. Edwards, W. Hugo, E.W. Trotter, M.R. Girotti, N.L. Stephenson, and et al. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors Nat Commun 5 2014 3901
14. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman, and et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 18 2012 1694 1703
15. A. Ribas, R. Gonzalez, A. Pavlick, O. Hamid, T.F. Gajewski, A. Daud, and et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: A phase 1b study Lancet Oncol 15 2014 954 965
16. G.V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. de Braud, J. Larkin, and et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma N Engl J Med 386 9992 2014 444 451
17. J. Larkin, P.A. Ascierto, B. Dreno, V. Atkinson, G. Liszkay, M. Maio, and et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma N Engl J Med 371 2014 1867 1876
18. E.M. Van Allen, N. Wagle, A. Sucker, D.J. Treacy, C.M. Johannessen, E.M. Goetz, and et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discov 4 2014 94 109
19. H. Rizos, A.M. Menzies, G.M. Pupo, M.S. Carlino, C. Fung, J. Hyman, and et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact Clin Cancer Res 20 2014 1965 1977
20. H. Shi, W. Hugo, X. Kong, A. Hong, R.C. Koya, G. Moriceau, and et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy Cancer Discov 4 2014 80 93
21. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, and et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
22. H. Zou, and T. Hastie Regularization and variable selection via the elastic net J R Stat Soc 67 2005 301 320
23. G. Fernandez Statistical data mining using SAS applications 2nd ed. 2010 CRC Press
24. A.M. Menzies, R.F. Kefford, and G.V. Long Paradoxical oncogenesis: Are all BRAF inhibitors equal? Pigment Cell Melanoma Res 26 2013 611 615
25. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, and et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
26. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, O. Spleiss, and et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
27. J. Villanueva, J.R. Infante, C. Krepler, P. Reyes-Uribe, M. Samanta, H.Y. Chen, and et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma Cell Rep 4 2013 1090 1099
28. N. Wagle, E.M. Van Allen, D.J. Treacy, D.T. Frederick, Z.A. Cooper, A. Taylor-Weiner, and et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition Cancer Discov 4 2014 61 68
29. G. Moriceau, W. Hugo, A. Hong, H. Shi, X. Kong, C.C. Yu, and et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction Cancer Cell 27 2015 240 256
30. M.S. Carlino, C. Fung, H. Shahheydari, J.R. Todd, S.C. Boyd, M. Irvine, and et al. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients Clin Cancer Res 21 2015 98 105
31. P.A. Ascierto, E. Simeone, D. Giannarelli, A.M. Grimaldi, A. Romano, and N. Mozzillo Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithm for clinical use J Transl Med 10 2012 107
32. A. Ackerman, O. Klein, D.F. McDermott, W. Wang, N. Ibrahim, D.P. Lawrence, and et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors Cancer 11 2014 1695 1701
33. H. Kakavand, J.S. Wilmott, A.M. Menzies, R. Vilain, L.E. Haydu, J.H. Yearley, and et al. PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients Clin Cancer Res 21 14 2015 3140 3148
34. D. Tompers Frederick, A. Piris, A.P. Cogdill, Z.A. Cooper, C. Lezcano, C.R. Ferrone, and et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clin Cancer Res 9 5 2013 1225 1231
35. S. Hu-Lieskovan, L. Robert, B. Homet Moreno, and A. Ribas Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges J Clin Oncol 32 21 2014 2248 2254